LIA
FLGT icon

LS Investment Advisors’s Fulgent Genetics FLGT Stock Holding History

LS Investment Advisors’s Portfolio FLGT Stock Details FLGT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-5,873
Closed -$567K – 369
2021
Q1 		$567K Sell
5,873
-235
-4% -$24.3K 0.03% 349
2020
Q4 		$318K Buy
+6,108
New +$255K 0.02% 605

Other funds holding FLGT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
NI
Nepsis Inc Minneapolis, Minnesota $295M AUM 35.44% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

LS Investment Advisors's FLGT Position: Q2 2021 in Review

LS Investment Advisors sold out of Fulgent Genetics (FLGT) in Q2 2021, closing a stake of 5,873 shares — an estimated $567K sold.

LS Investment Advisors first reported a position in FLGT in Q4 2020 and held it in 2 quarters. The position peaked at $567K in Q1 2021. 254 funds tracked by Wall St. Rank hold FLGT as of Q2 2021.

  • LS Investment Advisors reported no remaining Fulgent Genetics position as of Q2 2021 after selling out during the quarter.
  • LS Investment Advisors sold 5,873 Fulgent Genetics shares in Q2 2021, an estimated $567K.
  • LS Investment Advisors first reported a position in Fulgent Genetics in Q4 2020 and held it in 2 quarters.
  • LS Investment Advisors's Fulgent Genetics position peaked at $567K in Q1 2021.
  • 254 funds tracked by Wall St. Rank held Fulgent Genetics as of Q2 2021.

Based on LS Investment Advisors's 13F filing for Q2 2021, filed 11 Aug 2021.